Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Department of Dermatology, St George Hospital, Sydney, NSW, Australia.
Clin Exp Dermatol. 2022 Aug;47(8):1438-1445. doi: 10.1111/ced.15174. Epub 2022 May 25.
Psoriasis is a chronic inflammatory skin disease with complex comorbidities. Recent evidence has revealed how the inflammatory nature of psoriasis affects bone mineral density and may lead to osteoporosis. This review outlines the current understanding and advances on the association between psoriasis and osteoporosis. The current literature suggests an increased risk of osteopenia and osteoporosis in patients with extensive and chronic psoriasis, compounded by other lifestyle and genetic factors. It suggests that prophylactic measures such as vitamin D supplementation and increasing weight-bearing exercises can help, but in patients with extensive psoriasis, prolonged systemic inflammation may require long-term management. Although there have been many short-term RCTs on the efficacy and safety of biologics in psoriasis, clinical studies looking at the long-term effects of biologics, such as whether they might improve bone mineral density in these patients with psoriasis are yet to be conducted.
银屑病是一种慢性炎症性皮肤病,伴有多种合并症。最近的证据揭示了银屑病的炎症性质如何影响骨密度,并可能导致骨质疏松症。本综述概述了目前对银屑病和骨质疏松症之间关联的理解和进展。目前的文献表明,广泛和慢性银屑病患者的骨量减少和骨质疏松症风险增加,此外还有其他生活方式和遗传因素的影响。这表明预防性措施,如维生素 D 补充和增加负重运动可能有所帮助,但对于广泛的银屑病患者,长期的系统性炎症可能需要长期管理。尽管已经有许多关于生物制剂治疗银屑病的短期 RCT 研究,但仍需要进行临床研究来观察生物制剂的长期效果,例如它们是否可能改善这些银屑病患者的骨密度。